{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-093263","form_type":"8-K","ticker":"TCRT","cik":"0001107421","company_name":"Alaunos Therapeutics, Inc.","filed_at":"2025-07-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.354409+00:00","generated_at":"2026-05-18T09:34:48.086457+00:00","sec_items":["3.01","5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Alaunos Therapeutics CEO resigns; Holger Weis appointed; audit committee shortfall triggers Nasdaq notice","bullets":["Dale Curtis Hogue Jr. resigned as CEO and director effective July 1, 2025; no disagreement.","Holger Weis appointed CEO July 2, 2025; $275,000 base salary; option for 130,000 shares at $5.06.","Weis resigned from audit and compensation committees, causing non-compliance with Nasdaq Rule 5605(c); company intends to use 180-day grace period.","Hogue entered consulting agreement at $250/hour for strategic advisory services."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-093263","json":"https://secwatch.observer/filing/0000950170-25-093263.json","markdown":"https://secwatch.observer/filing/0000950170-25-093263.md","text":"https://secwatch.observer/filing/0000950170-25-093263.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1107421/000095017025093263/0000950170-25-093263-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1107421/000095017025093263/tcrt-20250701.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:34:48.086457+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}